• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

JGH Open . Comparison of liver fibrosis scores and fatty liver on computed tomography as risk factors for severity of COVID-19

tetano

Editor, Senior Moderator
JGH Open


. 2024 Aug 8;8(8):e70004.
doi: 10.1002/jgh3.70004. eCollection 2024 Aug. Comparison of liver fibrosis scores and fatty liver on computed tomography as risk factors for severity of COVID-19

Yuji Kamiya[SUP] 1 [/SUP], Masahiro Shinoda[SUP] 2 [/SUP], Naoki Ishii[SUP] 3 [/SUP], Saki Yamamoto[SUP] 1 [/SUP], Tetsuo Sekine[SUP] 1 [/SUP], Miwa Morikawa[SUP] 2 [/SUP], Shinichiro Ota[SUP] 2 [/SUP], Mio Toyama-Kousaka[SUP] 2 [/SUP], Hidenori Takahashi[SUP] 2 [/SUP], Hiroaki Takei[SUP] 2 [/SUP], Masaharu Shinkai[SUP] 2 [/SUP]



Affiliations
Abstract

Background and aim: Increased liver fibrosis scores (LFS), such as fibrosis-4 index (FIB-4) or non-alcoholic fatty liver disease fibrosis score (NFS), and fatty liver are known risk factors for severe coronavirus disease 2019 (COVID-19). The purpose of this study was to identify the best scores, which predict the prognosis of COVID-19.
Methods: Participants comprised consecutive Japanese COVID-19 patients admitted to our hospital between February 14, 2020, and April 14, 2021. Multivariate logistic regression analysis was performed to evaluate the relationships between LFS (FIB-4, NFS, aspartate aminotransferase-to-platelet ratio index [APRI], BARD score, and hepatic steatosis index [HSI]) or fatty liver on computed tomography (CT), and severity of COVID-19.
Results: Of the 415 patients (mean age, 59 years), 177 patients (42.7%) needed oxygen therapy, 90 patients (21.7%) worsened to severe COVID-19, and 45 patients (10.8%) died during admission. Multivariate logistic regression analysis showed that increased FIB-4 and NFS were risk factors for death, severe COVID-19, and oxygen demand; that increased BARD was a risk factor for severe COVID-19 and oxygen demand; and that increased APRI and HSI were not risk factors for any status of COVID-19. Furthermore, increased NFS or BARD and fatty liver were independent risk factors for severe COVID-19 and oxygen demand.
Conclusions: This study showed that FIB-4 and NFS were the best liver fibrosis scores that predicted worse prognosis for COVID-19, and that increased NFS or BARD and fatty liver evident on CT represented independent risk factors for severe COVID-19 and oxygen demand.

Keywords: COVID‐19; fatty liver; liver fibrosis scores; risk factors.

 
Back
Top Bottom